Hong Kong Stocks Movement | JUNSHI BIO (01877) Surges Over 6% as More Than 20 Studies Including Toripalimab Set to Be Presented at ESMO 2025 Conference

Stock News

Sep 25

JUNSHI BIO (01877) surged over 6%, and as of press time, the stock was up 6.34% to HK$31.54, with a turnover of HK$182 million.

On the news front, according to JUNSHI BIO's official announcement, the 2025 European Society for Medical Oncology (ESMO) Congress will be held from October 17 to October 21, 2025, in Berlin, Germany. More than 20 studies from JUNSHI BIO's innovative products, including anti-PD-1 monoclonal antibody Toripalimab, anti-BTLA monoclonal antibody tifcemalimab, and selective PI3K-α inhibitor JS105, will be presented at this conference.

Recently, the conference's official website announced the selection results for this year's Late-Breaking Abstracts (LBA). Two studies of Toripalimab were successfully selected for LBA oral presentations at the conference, with one study even making it into the conference's highest honor session - the Proffered Paper session LBA oral presentation, demonstrating the cutting-edge progress of Toripalimab combination therapies. Previously, the conference had already announced the selection status of other studies excluding LBA.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1122097843"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122097843\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122097843?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-25 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122097843","market":"sg","top_or_hot":-1,"title":"Hong Kong Stocks Movement | JUNSHI BIO (01877) Surges Over 6% as More Than 20 Studies Including Toripalimab Set to Be Presented at ESMO 2025 Conference","media":"Stock News","content":"<p>JUNSHI BIO (01877) surged over 6%, and as of press time, the stock was up 6.34% to HK$31.54, with a turnover of HK$182 million.</p>\n<p>On the news front, according to JUNSHI BIO's official announcement, the 2025 European Society for Medical Oncology (ESMO) Congress will be held from October 17 to October 21, 2025, in Berlin, Germany. More than 20 studies from JUNSHI BIO's innovative products, including anti-PD-1 monoclonal antibody Toripalimab, anti-BTLA monoclonal antibody tifcemalimab, and selective PI3K-α inhibitor JS105, will be presented at this conference.</p>\n<p>Recently, the conference's official website announced the selection results for this year's Late-Breaking Abstracts (LBA). Two studies of Toripalimab were successfully selected for LBA oral presentations at the conference, with one study even making it into the conference's highest honor session - the Proffered Paper session LBA oral presentation, demonstrating the cutting-edge progress of Toripalimab combination therapies. Previously, the conference had already announced the selection status of other studies excluding LBA.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks Movement | JUNSHI BIO (01877) Surges Over 6% as More Than 20 Studies Including Toripalimab Set to Be Presented at ESMO 2025 Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks Movement | JUNSHI BIO (01877) Surges Over 6% as More Than 20 Studies Including Toripalimab Set to Be Presented at ESMO 2025 Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-25 10:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JUNSHI BIO (01877) surged over 6%, and as of press time, the stock was up 6.34% to HK$31.54, with a turnover of HK$182 million.</p>\n<p>On the news front, according to JUNSHI BIO's official announcement, the 2025 European Society for Medical Oncology (ESMO) Congress will be held from October 17 to October 21, 2025, in Berlin, Germany. More than 20 studies from JUNSHI BIO's innovative products, including anti-PD-1 monoclonal antibody Toripalimab, anti-BTLA monoclonal antibody tifcemalimab, and selective PI3K-α inhibitor JS105, will be presented at this conference.</p>\n<p>Recently, the conference's official website announced the selection results for this year's Late-Breaking Abstracts (LBA). Two studies of Toripalimab were successfully selected for LBA oral presentations at the conference, with one study even making it into the conference's highest honor session - the Proffered Paper session LBA oral presentation, demonstrating the cutting-edge progress of Toripalimab combination therapies. Previously, the conference had already announced the selection status of other studies excluding LBA.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"YANG","symbol_name":"三倍做空富时中国ETF-Direxion","start_time":0,"source_url":"","article_id":"1122097843","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122097843","pubTimestamp":1758767066,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JUNSHI BIO (01877) surged over 6%, and as of press time, the stock was up 6.34% to HK$31.54, with a turnover of HK$182 million. On the news front, according to JUNSHI BIO's official announcement, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","YANG":"三倍做空富时中国ETF-Direxion","07226":"南方两倍做多恒科","BK4614":"Manus概念股","BK0239":"医药制造","BK1515":"抗疫概念","BK1161":"生物科技","01877":"君实生物","HSCEI":"国企指数","BK1583":"高瓴概念"},"translate_title":"港股动向|君实生物(01877)涨超6%特瑞普利单抗等20多项研究将亮相ESMO 2025大会","themeId":"c5b51a21201fb2ede98245898f9416f5","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"01877":1,"07226":1,"HSCEI":1,"YANG":1},"content_text":"JUNSHI BIO (01877) surged over 6%, and as of press time, the stock was up 6.34% to HK$31.54, with a turnover of HK$182 million.\nOn the news front, according to JUNSHI BIO's official announcement, the 2025 European Society for Medical Oncology (ESMO) Congress will be held from October 17 to October 21, 2025, in Berlin, Germany. More than 20 studies from JUNSHI BIO's innovative products, including anti-PD-1 monoclonal antibody Toripalimab, anti-BTLA monoclonal antibody tifcemalimab, and selective PI3K-α inhibitor JS105, will be presented at this conference.\nRecently, the conference's official website announced the selection results for this year's Late-Breaking Abstracts (LBA). Two studies of Toripalimab were successfully selected for LBA oral presentations at the conference, with one study even making it into the conference's highest honor session - the Proffered Paper session LBA oral presentation, demonstrating the cutting-edge progress of Toripalimab combination therapies. Previously, the conference had already announced the selection status of other studies excluding LBA.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}